子宫肌瘤相关不孕症:机制与管理
本文综述子宫肌瘤与不孕症的关联争议、肌瘤损害生育力的可能机制及肌瘤相关不孕的处理。当前处理主要包括宫腔镜、开腹或腹腔镜子宫肌瘤剔除术,以及子宫动脉栓塞和影像引导下聚焦超声等非手术方法;口服促性腺激素释放激素拮抗剂(elagolix、relugolix、linzagolix)可在超过70%的女性中快速改善月经过多,未加反向添加治疗时从基线至第24周可使肌瘤体积减少约50%。
要点
- 肌瘤与不孕的关联存在争议,需分析肌瘤损害生育力的机制。
- 处理以手术(宫腔镜、开腹或腹腔镜肌瘤剔除)和非手术(子宫动脉栓塞、影像引导聚焦超声)为主。
- 口服GnRH拮抗剂在>70%女性中快速改善月经过多,未加反向添加时第24周肌瘤体积较基线减少约50%。
核心结论
- 肌瘤与不孕的关联存在争议,处理需结合患者因素、术者技能和各中心资源讨论各方案的风险与获益。
- 口服促性腺激素释放激素拮抗剂对月经过多有快速影响,未加反向添加治疗时可使肌瘤体积显著缩小。
- 若以缩小肌瘤体积为主要目标(如肌瘤相关不孕),确定最佳方案和最佳剂量仍需进一步研究。
研究设计与样本
- 综述,旨在批判性分析子宫肌瘤与不孕症的关联、肌瘤损害生育力的机制及肌瘤相关不孕的管理。
主要发现
- 口服促性腺激素释放激素拮抗剂(elagolix、relugolix、linzagolix)在>70%的女性中对月经过多有快速影响。
- 未加反向添加治疗时,这些药物使肌瘤体积从基线至第24周显著缩小,约50%。
临床怎么用
- 当前管理策略主要包括手术治疗,即宫腔镜、开腹或腹腔镜子宫肌瘤剔除术。
- 非手术方法包括子宫动脉栓塞和放射学或超声引导下聚焦超声。
- 应与患者讨论每种选择的风险与获益,并考虑术者技能和各中心不同资源的可及性。
局限性
- 若以缩小肌瘤体积为主要目标(如肌瘤相关不孕),确定最佳方案和最佳剂量仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroids are a common pathology and increasingly observed in women seeking medical treatment for infertility. The longer reproductive horizon because of improvements in medical care and current trend for women to postpone childbearing are making fibroid-related infertility increasingly common. This review aimed to critically analyze the association between uterine fibroids and infertility, mechanisms by which uterine fibroids may impair fertility, and management of myoma-related infertility. The association of fibroids with infertility is a source of controversy. As the focus of this review is infertility, it is crucial to analyze the mechanisms by which fertility may be impaired by the presence of fibroids. Current management strategies involve mainly surgical interventions, including myomectomy by hysteroscopy, laparotomy, or laparoscopy, and nonsurgical approaches, such as uterine artery embolization and focused ultrasound performed under radiologic or echographic guidance. The risks and benefits of each option should be discussed with patients, and several factors need to be considered, including the skills of surgeons and availability of different resources in various centers. Concerning the efficacy of oral gonadotropin-releasing hormone antagonists (i.e., elagolix, relugolix, and linzagolix), they were shown to have a rapid impact on heavy menstrual bleeding (HMB) in >70% of women. When used without add-back therapy, these drugs cause a significant reduction in fibroid volume, namely, approximately 50% from baseline to week 24. Further studies are required to determine the best protocol and optimal dosage if a reduction in myoma volume is the main goal, as in case of myoma-related infertility.
引用
- Donnez J, Taylor HS, Marcellin L, et al. Uterine fibroid-related infertility: mechanisms and management. Fertil Steril. 2024. PMID: 38453041. doi:10.1016/j.fertnstert.2024.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。